Denosumab for prevention of fractures in postmenopausal women with osteoporosis
about
Reproducibility of results in preclinical studies: a perspective from the bone fieldThe pharmacological management of osteoporosisOsteoclast differentiation factor RANKL controls development of progestin-driven mammary cancerEuropean guidance for the diagnosis and management of osteoporosis in postmenopausal womenBiomarkers of the osteoprotegerin pathway: clinical correlates, subclinical disease, incident cardiovascular disease, and mortalityEffect of denosumab on Japanese patients with rheumatoid arthritis: a dose-response study of AMG 162 (Denosumab) in patients with RheumatoId arthritis on methotrexateSurgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature reviewRoles and Clinical Applications of OPG and TRAIL as Biomarkers in Cardiovascular DiseaseTreating osteoporosisThe Relationship between Metabolic Syndrome and Osteoporosis: A ReviewManagement of chronic pain in osteoporosis: challenges and solutionsHypercalcemia of Malignancy: An Update on Pathogenesis and ManagementPrevention and treatment of bone fragility in cancer patientEfficacy and Safety of Denosumab in Postmenopausal Women With Osteoporosis: A Meta-AnalysisUpdate on denosumab in the management of postmenopausal osteoporosis: patient preference and adherenceRecent developments in osteogenesis imperfectaEmerging Therapies for OsteoporosisManaging Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral ResearchCalcium intake and bone mineral density: systematic review and meta-analysisDenosumab, a RANK ligand inhibitor, for the management of bone loss in cancer patientsOsteochemonecrosis: an overviewNuclear receptors in bone physiology and diseasesOsteoporosis Treatment: When to Discontinue and When to Re-startPostmenopausal osteoporosis treatment with antiresorptives: effects of discontinuation or long-term continuation on bone turnover and fracture risk--a perspectiveTreatment of primary osteoporosis in menScreening, diagnosis and treatment of osteoporosis: a brief reviewA review of denosumab for the treatment of osteoporosisEpidemiology and management of osteoporosis in the People's Republic of China: current perspectivesDenosumab for the treatment of osteoporosisA new WNT on the bone: WNT16, cortical bone thickness, porosity and fracturesAn overview on the treatment of postmenopausal osteoporosisNew antiresorptive therapies for postmenopausal osteoporosisDenosumab: mechanism of action and clinical outcomesBone targeted therapies for the prevention of skeletal morbidity in men with prostate cancerStructure-based development of a receptor activator of nuclear factor- B ligand (RANKL) inhibitor peptide and molecular basis for osteopetrosisDesign and pharmacology of a highly specific dual FMS and KIT kinase inhibitorBone anabolics in osteoporosis: Actuality and perspectivesNonsurgical Treatment Strategies after Osteoporotic Hip Fractures.The epidemiology and management of postmenopausal osteoporosis: a viewpoint from BrazilLipid metabolism disorders and bone dysfunction--interrelated and mutually regulated (review)
P2860
Q24289530-46B3AFD3-01FA-48C6-A2BB-3FD442212B53Q24605290-1088701E-F968-46E1-B634-6D40C83AFA38Q24605866-4D76BC7F-235C-4918-9E01-5AF185C90F60Q24612411-C819BEC8-B546-4578-8626-AA662756E1A1Q24623768-3460298E-85DD-499B-9E66-02CD4AD47D52Q24658507-69DCCEAF-8A91-42DB-8424-1C0C7FD9CF29Q26744057-E73A689F-7A49-4332-A764-A714E6DE0F1BQ26747224-4250E240-FA2D-402E-83A9-05423D6916DDQ26747363-81CC5284-C694-4A73-8B9E-17F6EE7A9447Q26747451-A1CBDAA3-B6D6-40D3-AF5B-417EFB88DD15Q26751333-0DA4AFE1-43C0-4C32-970D-C0EB17277320Q26771719-187B6AEF-4F31-4D64-927C-0092ABF32134Q26775765-37105BA2-C765-4934-872D-21788AE70B70Q26778216-190A4E82-98D0-432E-A626-AF5137D11683Q26778291-8088794D-045B-4E7A-9E29-52CB96CF5041Q26781674-8B172263-338B-4C79-B78F-7BC84AF96E3DQ26782109-C4EEE9F0-3DC3-4019-BD1B-85E30EBECA59Q26782621-0C56E4F5-A481-4190-A595-74B5D89FF31FQ26784337-DA40DF33-45A9-4F57-B03B-E1AF9062CBF3Q26824762-AF57A0C9-D49A-4929-A2B3-010AE95D0772Q26827072-6635F37F-4558-459C-973D-41E96B833338Q26853017-5CF71C3A-4410-4BC2-A21E-85DF756B3C10Q26858980-AF197E72-DE10-4C35-966F-523B64D99CCEQ26864207-FE4648BA-3790-4C02-BEDE-C7B5B7B5A10EQ26991748-6B63D65E-2260-44CD-92F7-CDBC5630F026Q26996726-37533307-8A3D-4A61-838C-EC725F60A0F6Q27005894-E37C0BF7-27F2-41AF-8FA7-EF4477E55CDDQ27005978-AA7B1CBD-FAA3-45D2-9647-4E79893315CFQ27009275-D0F25187-CAA0-43FE-83F5-DA0B89AC39E3Q27009420-B3D1DDAC-4B26-46F6-ADDC-CFD2632B3881Q27013070-31E0AD1D-1303-4C81-8C00-4CFB4C038E5FQ27014775-57D26448-8079-418D-93C9-C257A3D94DA7Q27015899-259FC673-2F43-4EB9-9F68-89B90F3AE520Q27021268-79ACDF64-E8B4-46E3-9A15-3B2F5E1DF447Q27665673-538D5F6F-0570-439F-9CF1-6424DE2524E4Q27676827-7390C0DE-A514-4BBD-BDA0-896112405056Q27691122-423F3C34-7FD8-428C-963A-297DC89C3C14Q27693845-64E3EC1E-89B1-4CC6-9C1B-31773276A628Q28080673-3503891A-28A1-47C9-835D-3C0657C3AC57Q28083206-06546F4F-04AA-4AA8-A489-0112D980150E
P2860
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
description
2009 nî lūn-bûn
@nan
2009 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@ast
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@en
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@nl
type
label
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@ast
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@en
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@nl
prefLabel
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@ast
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@en
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@nl
P2093
P3181
P356
P1476
Denosumab for prevention of fractures in postmenopausal women with osteoporosis
@en
P2093
Andrea Wang
Cesar Libanati
Claus Christiansen
Ethel S Siris
Holly B Zoog
Javier San Martin
Jose Zanchetta
Matt Austin
Pierre Delmas
Richard Eastell
P304
P3181
P356
10.1056/NEJMOA0809493
P407
P577
2009-08-20T00:00:00Z